CKI 7 dihydrochloride: Selective Casein Kinase 1 Inhibitor for Signaling Pathway Research

Executive Summary: CKI 7 dihydrochloride is a potent, cell-permeable inhibitor of Casein kinase 1 (CK1), a serine/threonine kinase pivotal in diverse cellular processes including Wnt signaling, circadian rhythm regulation, and DNA repair (APExBIO product page). This compound demonstrates high selectivity for CK1, allowing precise modulation of protein phosphorylation in experimental models (ct99021.com). Its efficacy has been demonstrated in studies elucidating cancer metastasis mechanisms and apoptosis assays (Luo et al., 2026). CKI 7 dihydrochloride is supplied by APExBIO with validated stability and solubility profiles, supporting reproducible workflows. The compound is a gold-standard reagent for dissecting CK1-dependent signaling pathways in disease research and drug discovery.

Biological Rationale

Casein kinase 1 (CK1) is a serine/threonine protein kinase family conserved across eukaryotes. CK1 isoforms regulate processes such as circadian rhythm, cell cycle progression, Wnt/β-catenin signaling, and DNA repair (prazosinsmol.com). Aberrant CK1 activity has been implicated in oncogenesis, metastasis, and circadian rhythm disorders. For example, the Wnt/β-catenin pathway, regulated by CK1-mediated phosphorylation, governs cellular proliferation and is frequently dysregulated in cancers (Luo et al., 2026). CK1 also modulates circadian transcription factors and is thus essential for circadian homeostasis (solifenacinonline.com).

Pharmacological inhibition of CK1 enables precise investigation of these signaling cascades. CKI 7 dihydrochloride (N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide dihydrochloride) is widely employed for this purpose due to its high selectivity and cell permeability (APExBIO). It is a standard tool in cancer biology, apoptosis assays, and studies probing protein phosphorylation dynamics (ct99021.com). This article extends prior reviews by providing updated peer-reviewed evidence and practical integration guidance.

Mechanism of Action of CKI 7 dihydrochloride

CKI 7 dihydrochloride selectively inhibits the enzymatic activity of CK1 by occupying the ATP-binding site of the kinase, thereby blocking substrate phosphorylation (product specification). This prevents downstream phosphorylation events essential for Wnt/β-catenin signaling, circadian rhythm regulation, and DNA repair (solifenacinonline.com).

Specifically, CKI 7 dihydrochloride modulates the phosphorylation status of target proteins such as β-catenin, PER proteins (circadian regulators), and other CK1 substrates. In cancer models, CK1 inhibition has been shown to affect cell migration, invasion, and apoptosis (Luo et al., 2026). The compound is highly soluble in DMSO (up to 17.93 mg/ml) and moderately soluble in water (7.17 mg/ml), facilitating diverse assay formats (APExBIO).

Evidence & Benchmarks

• CKI 7 dihydrochloride inhibits CK1-mediated phosphorylation in vitro at low micromolar concentrations (IC₅₀ < 10 μM) under standard assay conditions (pH 7.4, 25°C) (APExBIO).
• CK1 inhibition by CKI 7 dihydrochloride disrupts Wnt/β-catenin signaling, reducing β-catenin stabilization and transcriptional activity in cell lines (ct99021.com).
• In NSCLC models, CK1 pathway modulation impacts metastasis-related protein phosphorylation, as shown by effects on KRT16 and MAPK10 signaling axes (Luo et al., 2026).
• CKI 7 dihydrochloride demonstrates high batch-to-batch consistency in solubility and purity when sourced from APExBIO, supporting reproducible results (pitolisantapis.com).
• CKI 7 dihydrochloride remains stable for >12 months at -20°C as a solid; solution storage for >1 month is not recommended (APExBIO).

Applications, Limits & Misconceptions

CKI 7 dihydrochloride is routinely used in:

• Dissecting Wnt/β-catenin and circadian rhythm regulatory pathways in cell and animal models (solifenacinonline.com).
• Apoptosis assays and cell proliferation studies, particularly in cancer biology research (ct99021.com).
• Functional genomics and proteomics to study CK1-dependent post-translational modifications (prazosinsmol.com).

This article updates mechanistic perspectives by integrating findings on CK1’s involvement in metastasis suppression through phosphorylation-dependent ubiquitination of KRT16, as described by Luo et al. (2026), and clarifies solubility/stability boundaries in contrast to practical workflow guides which focus on technical implementation.

Common Pitfalls or Misconceptions

• Non-selectivity at high concentrations: Doses above 50 μM may inhibit kinases other than CK1, leading to off-target effects.
• Ineffective in CK1-independent pathways: CKI 7 dihydrochloride will not impact signaling pathways that do not require CK1-mediated phosphorylation.
• Instability in aqueous solutions: The compound degrades rapidly in water above 4°C or when stored for >1 month.
• Not a genetic knockout: CKI 7 dihydrochloride does not recapitulate the effects of CK1 gene deletion; residual kinase activity may remain.
• Not suitable for in vivo systemic administration without PK/PD optimization: Systemic use requires validation of pharmacokinetics and toxicity.

Workflow Integration & Parameters

For optimal results, prepare CKI 7 dihydrochloride stock solutions in DMSO at ≤17.93 mg/ml and store aliquots at -20°C. Working dilutions should be freshly prepared in assay buffers. Avoid repeated freeze-thaw cycles and do not store solutions for extended periods. APExBIO ships the compound on blue ice to ensure stability (product page).

For cell-based assays, use concentrations between 1–20 μM, validating pathway inhibition via Western blot or reporter assays. For biochemical kinase assays, adjust buffer pH to 7.4 and maintain at 25°C for consistent activity. Refer to this article for comparison of selectivity profiles, and narlaprevircompound.com for additional workflow recommendations. This article extends prior guidance by integrating recent mechanistic and stability data.

Conclusion & Outlook

CKI 7 dihydrochloride, supplied by APExBIO, is a benchmark Casein kinase 1 inhibitor supporting high-precision research in Wnt signaling, circadian regulation, and cancer biology. Its validated selectivity, solubility, and stability enable reproducible pathway modulation and mechanistic studies. As new evidence emerges linking CK1 activity to disease progression and therapeutic responses, CKI 7 dihydrochloride will remain an essential tool for experimental biology and drug discovery (Luo et al., 2026).